Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R. Kurth K, et al. J Urol. 1997 Aug;158(2):378-84. doi: 10.1016/s0022-5347(01)64484-7. J Urol. 1997. PMID: 9224307 Clinical Trial.
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L; Members of the EORTC Genito-Urinary Group. Schröder FH, et al. Eur Urol. 2004 Apr;45(4):457-64. doi: 10.1016/j.eururo.2003.11.016. Eur Urol. 2004. PMID: 15041109 Clinical Trial.
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P; European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. de Reijke TM, et al. Among authors: kurth kh. J Urol. 2005 Feb;173(2):405-9. doi: 10.1097/01.ju.0000150425.09317.67. J Urol. 2005. PMID: 15643181 Clinical Trial.
Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
Kurth K, Schroeder FH, Debruyne F, Senge T, Pavone-Macaluso M, de Pauw M, ten Kate F, Sylvester R. Kurth K, et al. Prog Clin Biol Res. 1989;303:481-90. Prog Clin Biol Res. 1989. PMID: 2675005 Clinical Trial. No abstract available.
Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.
Kurth KH, Schröder FH, Tunn U, Ay R, Pavone-Macaluso M, Debruyne F, de Pauw M, Dalesio O, ten Kate F. Kurth KH, et al. J Urol. 1984 Aug;132(2):258-62. doi: 10.1016/s0022-5347(17)49582-6. J Urol. 1984. PMID: 6376827 Clinical Trial.
184 results